Paper Details

  1. Home
  2. Paper Details

Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.

Author: AdlerSabine, BütikoferLukas, DanDiana, FiegeVeronika, KuchenStefan, ReichenbachStephan, SeitzMichael, VilligerPeter M, WermelingerFelix

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Giant cell arteritis (GCA) is an inflammatory condition that affects large arteries, mainly affecting people over 50. While corticosteroids are the standard treatment and can prevent serious complications, they can also cause harm. Tocilizumab, a medication that blocks a specific inflammatory protein, has shown promise in treating GCA. This study is the first randomized clinical trial to investigate the effectiveness and safety of tocilizumab in newly diagnosed or recurring GCA.
Paper Details　
Original Abstract of the Article :
Giant cell arteritis is an immune-mediated disease of medium and large-sized arteries that affects mostly people older than 50 years of age. Treatment with glucocorticoids is the gold-standard and prevents severe vascular complications but is associated with substantial morbidity and mortality. Toci...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S0140-6736(16)00560-2

データ提供：米国国立医学図書館（NLM）

Tocilizumab: A New Hope for Giant Cell Arteritis

Giant cell arteritis, a debilitating condition that affects the blood vessels, can feel like a relentless sandstorm, causing inflammation and pain. This study explores the potential of tocilizumab, a humanised monoclonal antibody, as a new treatment option for giant cell arteritis. The study employed a phase 2, randomised, double-blind, placebo-controlled trial design to assess the efficacy and safety of tocilizumab in patients with newly diagnosed or recurrent giant cell arteritis.

A Potential Oasis in the Desert of Giant Cell Arteritis

The research found that tocilizumab demonstrated promising results in inducing and maintaining remission in patients with giant cell arteritis. This finding suggests that tocilizumab may offer a potential alternative to traditional treatment with glucocorticoids, which often have significant side effects. It’s like finding a cool spring in the middle of a scorching desert – a welcome relief from the relentless heat.

Navigating the Shifting Sands of Treatment Options

This study sheds light on the evolving landscape of giant cell arteritis treatment. The research highlights the importance of exploring new therapies, like tocilizumab, that can provide effective treatment with fewer side effects. It's a reminder that the desert of medical research is constantly shifting, revealing new opportunities for addressing complex health challenges.

Dr. Camel's Conclusion

Tocilizumab offers a beacon of hope for patients with giant cell arteritis. The study provides compelling evidence for its potential to effectively treat this debilitating condition with fewer side effects than traditional treatments. This research is a testament to the enduring spirit of scientific exploration, uncovering new pathways to combat the challenges of health and disease.

Date :
  1. Date Completed 2016-06-07
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

26952547

DOI: Digital Object Identifier

10.1016/S0140-6736(16)00560-2

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.